[go: up one dir, main page]

SG11201406301TA - Clostridium difficile antigens - Google Patents

Clostridium difficile antigens

Info

Publication number
SG11201406301TA
SG11201406301TA SG11201406301TA SG11201406301TA SG11201406301TA SG 11201406301T A SG11201406301T A SG 11201406301TA SG 11201406301T A SG11201406301T A SG 11201406301TA SG 11201406301T A SG11201406301T A SG 11201406301TA SG 11201406301T A SG11201406301T A SG 11201406301TA
Authority
SG
Singapore
Prior art keywords
clostridium difficile
difficile antigens
antigens
clostridium
difficile
Prior art date
Application number
SG11201406301TA
Inventor
Clifford Shone
April Roberts
Michael Maynard-Smith
Original Assignee
Sec Dep For Health
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sec Dep For Health filed Critical Sec Dep For Health
Publication of SG11201406301TA publication Critical patent/SG11201406301TA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/08Clostridium, e.g. Clostridium tetani
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/40Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum bacterial
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1282Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Clostridium (G)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10Transferases (2.)
    • C12N9/1048Glycosyltransferases (2.4)
    • C12N9/1051Hexosyltransferases (2.4.1)
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911Bacteria
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507Comprising a combination of two or more separate antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55566Emulsions, e.g. Freund's adjuvant, MF59
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54F(ab')2
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/60Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622Single chain antibody (scFv)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90Enzymes; Proenzymes
    • G01N2333/91Transferases (2.)
    • G01N2333/91091Glycosyltransferases (2.4)
    • G01N2333/91097Hexosyltransferases (general) (2.4.1)
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00Immunoassays for the detection of microorganisms
    • G01N2469/10Detection of antigens from microorganism in sample from host
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00Immunoassays for the detection of microorganisms
    • G01N2469/20Detection of antibodies in sample from host which are directed against antigens from microorganisms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Mycology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
SG11201406301TA 2012-04-04 2013-04-04 Clostridium difficile antigens SG11201406301TA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1206070.3A GB201206070D0 (en) 2012-04-04 2012-04-04 Clostridium difficile antigens
PCT/GB2013/050886 WO2013150309A1 (en) 2012-04-04 2013-04-04 Clostridium difficile antigens

Publications (1)

Publication Number Publication Date
SG11201406301TA true SG11201406301TA (en) 2014-11-27

Family

ID=46160352

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201406301TA SG11201406301TA (en) 2012-04-04 2013-04-04 Clostridium difficile antigens

Country Status (11)

Country Link
US (2) US9315555B2 (en)
EP (1) EP2844283B1 (en)
JP (1) JP2015516964A (en)
CN (1) CN104755099A (en)
AU (1) AU2013245412A1 (en)
BR (1) BR112014024751A2 (en)
CA (1) CA2869109A1 (en)
GB (1) GB201206070D0 (en)
IN (1) IN2014DN08325A (en)
SG (1) SG11201406301TA (en)
WO (1) WO2013150309A1 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE033342T2 (en) 2010-09-03 2017-11-28 Valneva Austria Gmbh C. difficile toxin A and toxin B proteins are isolated polypeptides and their applications
GB201206070D0 (en) * 2012-04-04 2012-05-16 Health Prot Agency Clostridium difficile antigens
SG11201510166YA (en) 2013-06-14 2016-01-28 Sanofi Pasteur Inc Compositions and methods of immunizing against c. difficile
MX2017014666A (en) * 2015-05-15 2018-02-09 Sanofi Pasteur Inc Methods for immunizing against clostridium difficile.
EP3433264A4 (en) * 2016-03-21 2019-08-28 Children's Medical Center Corporation COMPOSITIONS AND METHODS FOR INHIBITING WNT SIGNALING
CN112512556A (en) * 2018-01-16 2021-03-16 儿童医学中心公司 Compositions and methods for inhibiting WNT signaling
CN113329766A (en) * 2018-11-16 2021-08-31 马特里瓦克斯公司 Clostridium difficile multicomponent vaccine
US12161691B2 (en) 2019-05-11 2024-12-10 The Texas A&M University System Protein inhibitors of clostridium difficile toxin b
EP3972638A4 (en) * 2019-05-21 2023-09-13 The Regents Of The University Of California VACCINE COMPOSITIONS FOR CLOSTRIDIUM DIFFICILE
CN113717263B (en) * 2021-08-04 2022-06-07 河北医科大学第二医院 A Clostridium difficile-specific antigenic peptide
CN118613492A (en) * 2022-01-30 2024-09-06 西湖大学 TFPI-binding polypeptides and uses thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5601823A (en) 1989-10-31 1997-02-11 Ophidian Pharmaceuticals, Inc. Avian antitoxins to clostridium difficle toxin A
JP2002542169A (en) * 1999-04-09 2002-12-10 テクラブ, インコーポレイテッド Recombinant toxin A / toxin B vaccine against Clostridium difficile
EP1292686A1 (en) 2000-06-07 2003-03-19 Smittskyddsinstitutet Gene expression cassette and its use
GB0205206D0 (en) 2002-03-06 2002-04-17 Oxoid Ltd Synthetic peptides
JP4588763B2 (en) 2004-02-06 2010-12-01 ユニバーシティー オブ マサチューセッツ Antibodies against Clostridium difficile toxin and uses thereof
WO2008014733A1 (en) 2006-08-02 2008-02-07 Johannes Gutenberg-Universität Mainz Medicament for lct poisoning
US8889363B2 (en) 2009-07-27 2014-11-18 Biodics Method for the detection and identification of a variant C. difficile strain in a sample
CN102947334B (en) 2010-04-15 2017-12-26 普罗杰尼克制药股份有限公司 Antibodies for the treatment of Clostridium difficile-associated infections and diseases
GB201016742D0 (en) * 2010-10-05 2010-11-17 Health Prot Agency Clostridium difficile antigens
GB201206070D0 (en) * 2012-04-04 2012-05-16 Health Prot Agency Clostridium difficile antigens

Also Published As

Publication number Publication date
HK1202805A1 (en) 2015-10-09
IN2014DN08325A (en) 2015-05-15
US20160319037A1 (en) 2016-11-03
CN104755099A (en) 2015-07-01
JP2015516964A (en) 2015-06-18
EP2844283B1 (en) 2019-06-12
CA2869109A1 (en) 2013-10-10
GB201206070D0 (en) 2012-05-16
BR112014024751A2 (en) 2017-07-11
US9896514B2 (en) 2018-02-20
WO2013150309A9 (en) 2015-04-09
WO2013150309A1 (en) 2013-10-10
US20150093389A1 (en) 2015-04-02
AU2013245412A1 (en) 2014-10-16
EP2844283A1 (en) 2015-03-11
WO2013150309A8 (en) 2014-12-24
US9315555B2 (en) 2016-04-19

Similar Documents

Publication Publication Date Title
IL264558A (en) Anti-il-23p19 antibodies
ZA201407509B (en) Anti-fcrn antibodies
ZA201407897B (en) Protease-regulated antibodies
ZA201409358B (en) Anti-siglec- 15 antibodies
GB201016742D0 (en) Clostridium difficile antigens
SG11201400916XA (en) Clostridium difficile antibodies
SG11201406301TA (en) Clostridium difficile antigens
SG10201709290XA (en) Anti-H7cr Antibodies
IL232957A0 (en) Clostridium difficile toxin-based vaccine
EP2925362A4 (en) Antibodies against clostridium difficile
IL233794A0 (en) Anti-phospholipase d4 antibody
IL237172A0 (en) פוליפפטידים של clostridium difficile כתרכיבים
IL231661A0 (en) Clostridium difficile antibodies
GB201121149D0 (en) Clostridium difficile toxin-based vaccine
IL235188A0 (en) Anti-pdgf-c antibodies
GB201216749D0 (en) Antigen combinations
GB201200568D0 (en) Antigen combinations